Log in to search using one of your social media accounts:

 

FDA Grants Priority Review to Merck ’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Dateline City: KENILWORTH, N.J. Data Supporting Application to Be Presented at 2017 ASCO Annual MeetingKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, seeking approval for treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have already received two or more lines of chemotherapy....
Source: Merck.com - Product News - May 23, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS ® (raltegravir) 600 mg in the European Union
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck  (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ISENTRESS® (raltegravir) 600 mg film-coated tablets, in combination with other anti-retroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.Language: EnglishContact: MerckMedia:P...
Source: Merck.com - Product News - May 19, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Dateline City: KENILWORTH, N.J. Now Approved for First-Line Treatment in Patients Ineligible for Cisplatin-Containing Chemotherapy and Second-Line Treatment in Patients Who Have Disease Progression During or Following Platinum-Containing Chemotherapy or Within 12 Months of Neoadjuvant or Adjuvant Treatment with Platinum-Containing Chemotherapy KEYTRUDA is the Only Anti-PD-1 Therapy to Demonstrate Superior Overall Survival Versus Chemotherapy in Patients With Advanced Urothelial Carcinoma Post-Platinum FailureKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,...
Source: Merck.com - Product News - May 18, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news

Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA ® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the American Diabetes Association
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that 19 scientific presentations from Merck ’s diabetes pipeline and portfolio – including Phase 3 data for investigational ertugliflozin, additional analyses of JANUVIA® (sitagliptin), and real-world research – will be presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) in San Diego, June 9-13, 2017.Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-740-6179orInve...
Source: Merck.com - Product News - May 16, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression
Dateline City: KENILWORTH, N.J. First Approval for an Anti-PD-1 Therapy as a Combination in Metastatic Nonsquamous NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta®) and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression.Language: ...
Source: Merck.com - Product News - May 10, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

European Commission Approves KEYTRUDA ® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV
Dateline City: KENILWORTH, N.J. First Approval for KEYTRUDA in a Hematologic Malignancy in the EUKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL)who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.Language: EnglishContact: MerckMedia:...
Source: Merck.com - Product News - May 5, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Classical Hodgkin Lymphoma Keytruda MSD NYSE:MRK Source Type: news

Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck ’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C
Dateline City: KENILWORTH, N.J. Study Evaluated VA Population with High Incidence of Co-MorbiditiesKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered ZEPATIER®in the U.S. Department of Veterans Affairs (VA) healthcare system.Language: EnglishContact: Merck& Co., Inc.Media:Doris Li, 908-740-1903orMichael Close, 267-305-1211orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 90...
Source: Merck.com - Product News - April 21, 2017 Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK ZEPATIER Source Type: news

Merck to Present New Data on ZEPATIER ® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company ’s chronic hepatitis C virus (HCV) clinical development programs as well as real-world studies on ZEPATIER® (elbasvir and grazoprevir) 50mg/100mg tablets will be presented at the upcomingInternational Liver Congress ™ 2017. Seventeen scientific abstracts will be presented, including oral sessions featuring real-world data on chronic HCV-infected patients treated with ZEPATIER from the U.S.Language: ...
Source: Merck.com - Product News - April 5, 2017 Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK International Liver Congress MSD NYSE:MRK ZEPATIER Source Type: news

European Medicines Agency ’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Dateline City: KENILWORTH, N.J. Recommendation Is for Adult Patients Who Have Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who Are Transplant-Ineligible and Have Failed BVKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refract...
Source: Merck.com - Product News - March 24, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NYSE:MRK Source Type: news

Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA ® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Dateline City: KENILWORTH, N.J. Submission Based on Data from KEYNOTE-021 Trial, Cohort G, Which Enrolled Patients Regardless of PD-L1 ExpressionKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE @Merckread more (Source: Merck.com - Product News)
Source: Merck.com - Product News - January 10, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD NYSE:MRK Source Type: news

Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA ® (pembrolizumab)
Dateline City: WILMINGTON, D.E.& KENILWORTH, N.J.Additional pivotal studies evaluating Incyte ’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017WILMINGTON, D.E.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 inhibitor, with KEYTRUDA&...
Source: Merck.com - Product News - January 9, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news

KEYTRUDA ® (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1
Dateline City: KENILWORTH, N.J. KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, has been approved in Japan for the treatment of certain patients with PD-L1-positive unresectable advanced/recurrent non-small cell lung cancer (NSCLC) in the first- and second-line treatment settings at a fixed dose of 200 mg every three weeks. MS D will manufacture an...
Source: Merck.com - Product News - December 19, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NYSE:MRK Source Type: news

KEYTRUDA ® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dateline City: KENILWORTH, N.J. First Presentation of Patient-Reported Outcomes from KEYNOTE-024 Study of Patients with Metastatic NSCLC Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) Findings Presented in Plenary Session at 17 th World Conference on Lung CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive health-related quality of life (HRQoL) findings from an exploratory analysis from the phase 3 KEYNOTE-024 study investigating the use of KEYTRUDA® (pembrolizumab), the ...
Source: Merck.com - Product News - December 7, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK KETYRUDA MSD NSCLC NYSE:MRK Source Type: news

Updated KEYTRUDA ® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer...
Source: Merck.com - Product News - December 6, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD NYSE:MRK Source Type: news

KEYTRUDA ® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
Dateline City: KENILWORTH, N.J. Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding PatientsKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in two trials of patients with relapsed ...
Source: Merck.com - Product News - December 6, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK ASH Keytruda MSD NYSE:MRK Source Type: news

Updated KEYTRUDA ® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology
Dateline City: KENILWORTH, N.J. Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of AnalysisKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, achieved an overall response rate (ORR) of 41 percent (n=7/17) (90% CI, 21-64) with follow-up of up to 27 months in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), a type of non-...
Source: Merck.com - Product News - December 5, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK ASH Keytruda lymphoma MSD Source Type: news

New KEYTRUDA ® (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies
Dateline City: KENILWORTH, N.J. Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary SessionKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, across multiple thoracic malignancies, including non...
Source: Merck.com - Product News - November 30, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda NYSE:MRK Source Type: news

New KEYTRUDA ® (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology
Dateline City: KENILWORTH, N.J. Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral PresentationsKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data regarding the investigational use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with a range of blood cancers including classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, will be presented at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Dieg...
Source: Merck.com - Product News - November 22, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #MRK $MRK Keytruda MDS Merck pembrolizamab Source Type: news

Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
Dateline City: KENILWORTH, N.J. First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancer ’s (SITC) 31 st Annual MeetingKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with advanced bladder (urothelial) cancer previously treated with platinum-containing chemotherapy. As previously announced, KEYTRUDA was superior to invest...
Source: Merck.com - Product News - November 12, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news

New KEYTRUDA ® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting
Dateline City: KENILWORTH, N.J. First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 StudyKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer will be presented at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting, Nov. 9-13.Language: EnglishContact: MerckMedia:Pamela Eisel...
Source: Merck.com - Product News - November 7, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD SITC Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for ...
Source: Merck.com - Product News - October 24, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda Source Type: news

Merck ’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy.Language: ...
Source: Merck.com - Product News - October 21, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck ’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients
Dateline City: KENILWORTH, N.J. KEYNOTE-024, Published in The New England Journal of Medicine, Showed KEYTRUDA as Monotherapy Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with High Levels of PD-L1 Expression KEYNOTE-021, Cohort G, Published in The Lancet Oncology, Showed KEYTRUDA in Combination with Chemotherapy Demonstrated Superior Efficacy Compared to Chemotherapy Alone as First-Line Treatment; Trial Enrolled Patients Regardless of PD-L1 ExpressionKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United S...
Source: Merck.com - Product News - October 9, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer ESMO Keytruda MSD NYSE:MRK Source Type: news

KEYTRUDA ® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress
Dateline City: KENILWORTH, N.J. Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More) KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months compared to standard of care chemotherap...
Source: Merck.com - Product News - October 9, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer ESMO Keytruda MSD NYSE:MRK Source Type: news

Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA ® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
Dateline City: KENILWORTH, N.J. Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with Follow-Up Beyond 2.5 Years  in Patients with Ipilimumab-Refractory Advanced MelanomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, compared to investigator-choice chemotherapy with a crossover to KEYTRUDA design, in patients with ipilimumab-refractor...
Source: Merck.com - Product News - October 8, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Melanoma MSD Source Type: news

New KEYTRUDA ® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients
Dateline City: KENILWORTH, N.J. Results from Interim Analysis of Phase 2 KEYNOTE-052 Study to be Presented at ESMO 2016 Congress and Highlighted in ESMO Press Program First Presentation of Data Investigating KEYTRUDA in the Front Line Treatment of Bladder CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive findings from the phase 2 KEYNOTE-052 study investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in previously untreated patients with unresectable (inoperable) or metastatic ...
Source: Merck.com - Product News - October 8, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news

FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck ’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Dateline City: KENILWORTH, N.J. Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population Submissions Based on Data from KEYNOTE-024 Trial Showing Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Express High Levels of PD-L1KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) f...
Source: Merck.com - Product News - September 7, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD Source Type: news

Results from Merck ’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results fromC-EDGE CO-STAR.C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER ™ (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-...
Source: Merck.com - Product News - August 8, 2016 Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK Annals of Internal Medicine MSD ZEPATIER Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®(pembrolizumab), the company ’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherap y.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orA...
Source: Merck.com - Product News - August 8, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Merck ’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Dateline City: KENILWORTH, N.J. KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA ® (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more), met its primary endpoint. Language: English Contact: Merck Media: Pamela Eisele,...
Source: Merck.com - Product News - June 16, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA ® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
Dateline City: KENILWORTH, N.J. Fourth Designation for KEYTRUDA Follows Breakthrough Status in Advanced Melanoma, Non-Small Cell Lung Cancer, and Colorectal Cancer KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). This is the fourth Breakthrough Therapy...
Source: Merck.com - Product News - April 18, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Hodgkin Lymphoma Keytruda MSD NYSE:MRK Source Type: news

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English Contact: Merck Medi...
Source: Merck.com - Product News - April 13, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer FDA Head and Neck Cancer Keytruda NYSE:MRK Source Type: news

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Language: English ...
Source: Merck.com - Product News - April 13, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer FDA Head and Neck Cancer Keytruda NYSE:MRK Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA ® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA ® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: Englis...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Merck Receives FDA Approval of ZEPATIER ™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Dateline City: KENILWORTH, N.J. ZEPATIER Achieves High Cure Rates (SVR12) in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZEPATIER ™ (elbasvir and grazoprevir) for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection, with or w...
Source: Merck.com - Product News - January 28, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Hepatitis NYSE:MRK Source Type: news

Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
Dateline City: KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: Merc...
Source: Merck.com - Product News - December 19, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD pembrolizumab Source Type: news

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
Dateline City: KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). L...
Source: Merck.com - Product News - December 19, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD pembrolizumab Source Type: news

FDA Approves Expanded Indication for Merck ’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
Dateline City: KENILWORTH, N.J. KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. Language: English Conta...
Source: Merck.com - Product News - December 18, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD NYSE:MRK Source Type: news

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
Dateline City: KENILWORTH, N.J. KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic mel...
Source: Merck.com - Product News - December 18, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD NYSE:MRK Source Type: news

Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA ® (pembrolizumab) Combination Trial
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembr olizumab) in a Phase I study across multiple tumor types. Language: English read more (Source: Merck.com - Product News)
Source: Merck.com - Product News - December 10, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® (pembrolizumab) Combination Trial
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembrolizumab) in a Phase I study across multiple tumor types. Language: English read more (Source: Merck.com - Product News)
Source: Merck.com - Product News - December 10, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA ® (pembrolizumab) Data
Dateline City: KENILWORTH, N.J. New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, across a range of hematological cancers were presente...
Source: Merck.com - Product News - December 8, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK ASH cancer Keytruda NYSE:MRK Source Type: news

Merck Announces Initial Results for KEYTRUDA ® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
Dateline City: KENILWORTH, N.J. In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three studies investigating the use of KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, in combination with three other immunotherapies – epacadostat, IMLYGIC TM (talimogene laherparepvec), and ipilimumab – in patien...
Source: Merck.com - Product News - November 21, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
Dateline City: KENILWORTH, N.J. In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three studies investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination with three other immunotherapies – epacadostat, IMLYGICTM (talimogene laherp...
Source: Merck.com - Product News - November 21, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Dateline City: LONDON & KENILWORTH, N.J. Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYT...
Source: Merck.com - Product News - November 3, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA ® (pembrolizumab) in Advanced Colorectal Cancer
Dateline City: KENILWORTH, N.J. Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA ® (pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough The...
Source: Merck.com - Product News - November 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #cancer #Merck #MRK $MRK colorectal cancer Keytruda MSD NYSE:MRK Source Type: news

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Advanced Colorectal Cancer
Dateline City: KENILWORTH, N.J. Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorecta...
Source: Merck.com - Product News - November 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Merck ’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Dateline City: KENILWORTH, N.J. Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDA ® (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective. Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558 Courtney Ronaldo, 908-236-1108 or Investors: Teri Loxam, 908-740...
Source: Merck.com - Product News - October 26, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news